Synspira Therapeutics is developing SNSP003, a non-porcine enzyme replacement therapy, and SNSP113, an inhaled treatment aimed at difficult-to-treat lung infections. SNSP003 is intended to improve digestion for people with pancreatic insufficiency, while SNSP113 is designed to address drug-resistant infections, reduce inflammation, and thin mucus. The company is advancing these programs through preclinical development and early-stage clinical trials. The Cystic Fibrosis Foundation has expanded a research collaboration to support Synspira's development work. The Foundation committed up to $14 million in additional funding to these programs. Including prior support, the Foundation will have committed up to $22.55 million total for the development of these drugs since the initial 2017 agreement. Synspira is developing a new class of inhaled glycopolymer-based therapeutics to reduce pulmonary inflammation and infection in diseases including cystic fibrosis (CF), COPD, and pneumonia. Its lead candidate, SNSP113, is a modified polysaccharide glycopolymer designed to disrupt bacterial biofilms, increase bacterial permeability to potentiate antibiotics, reduce mucus viscosity, and promote lung clearance. SNSP113 completed a Phase 1a first-in-human single ascending dose safety and tolerability trial in healthy volunteers and is planned to advance into stable CF patients in 2018. Synspira holds an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled therapeutics. The company announced it received up to a $3 million development award from the Cystic Fibrosis Foundation to advance clinical development of SNSP113 for pulmonary complications of CF. Synspira is privately held and based in Cambridge, Mass. Synspira is developing inhalable glycopolymer-based therapeutics for pulmonary diseases. Its lead program, SNSP113, is a modified polysaccharide inhaled agent that preclinically disrupts bacterial biofilms, reduces mucus viscosity, decreases bacterial viability (including antibiotic-resistant Burkholderia cepacia), and potentiates approved antibiotics. The company holds an exclusive field license to Synedgen’s Glycomics Technology Platform and related pulmonary delivery assets. Synspira plans to initiate a Phase 1 first-in-humans safety study of SNSP113 early in 2018 and to explore additional indications including pneumonia and COPD. Financially, Synspira announced it secured $8 million from a private investor to advance the Phase 1 study. Founded in early 2017 and based in Boston, the company has appointed a founding Board of Directors to support clinical development.

Total raised

$25M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2020